DAPA ACT HF

If you are currently admitted to the hospital for acute heart failure related to a condition in which your heart is not pumping enough blood with each heartbeat, you may be eligible to participate in a clinical trial called DAPA ACT HF-TIMI 68. This trial is studying a drug called dapagliflozin, which is a tablet taken by mouth once a day.

Dapagliflozin is a drug that has been approved by the US Food and Drug Administration (FDA) to improve blood sugar control in patients with type 2 diabetes and to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes and either cardiovascular disease or cardiovascular risk factors. Subsequent research studies have demonstrated that dapagliflozin also reduces the risk of cardiovascular death or worsening heart failure in patients with chronic heart failure regardless of whether they have diabetes. This trial will determine if it is safe and beneficial to start dapagliflozin during hospital admission for acute heart failure.